本文關(guān)鍵詞： 非小細(xì)胞肺癌 血管內(nèi)皮生長(zhǎng)因子受體 表皮生長(zhǎng)因子受體　出處：《中國(guó)人民解放軍醫(yī)學(xué)院》2016年碩士論文　論文類(lèi)型：學(xué)位論文

【摘要】：目的 本實(shí)驗(yàn)主要研究非小細(xì)胞肺癌(NSCLC)患者中,EGFR與VEGFR-2基因的mRNA表達(dá)水平及EGFR突變情況,總結(jié)其與非小細(xì)胞肺癌患者臨床病理特征之間的關(guān)系,并分析基因表達(dá)水平之間的相關(guān)性,探討EGFR信號(hào)通路與VEGF/VEGFR信號(hào)通路的機(jī)制,為NSCLC患者合理使用抗表皮生長(zhǎng)因子受體和抗血管生成靶向藥物聯(lián)合治療提供一定的理論依據(jù)。方法 統(tǒng)計(jì)解放軍總醫(yī)院胸外科2014年至2015年共計(jì)128例確診非小細(xì)胞肺癌患者,記錄患者年齡、性別、吸煙史、病理類(lèi)型、分化程度、TNM分期等相關(guān)臨床資料信息。取樣手術(shù)新鮮標(biāo)本腫瘤組織或CT引導(dǎo)下經(jīng)皮肺腫瘤穿刺的腫瘤組織,使用液相芯片技術(shù)對(duì)腫瘤細(xì)胞的EGFR E18-21基因突變情況和EGFR、 VEGFR-2基因的mRNA表達(dá)水平進(jìn)行定量檢測(cè),應(yīng)用SPSS19.0統(tǒng)計(jì)軟件對(duì)所得數(shù)據(jù)進(jìn)行分析,統(tǒng)計(jì)有無(wú)相關(guān)性。結(jié)果本組患者EGFR基因突變率為47.7%,其中E1 9基因突變率為21.1%,E21基因的突變率為26.6%,無(wú)E18及E20基因突變。EGFR E19基因突變與吸煙史呈現(xiàn)顯著相關(guān)性(r=0.238, p0.01), EGFR E21基因發(fā)生突變與腫瘤病理類(lèi)型(r=-0.213,p0.05)和腫瘤分化程度(r=-0.190,p0.05)都呈現(xiàn)相關(guān)性。EGFR基因表達(dá)與腫瘤病理類(lèi)型相關(guān)(r=0.244,p0.01)。VEGFR-2的基因表達(dá)與腫瘤病理類(lèi)型(r=0.271,p0.01)和腫瘤分化程度(r=0.237,p0.01)都呈現(xiàn)相關(guān)性。EGFR與VEGFR-2的基因表達(dá)顯著相關(guān)(r=0.320,p0.01)。結(jié)論EGFR突變好發(fā)于19、21外顯子,其中無(wú)吸煙史患者易發(fā)生E19突變,腫瘤分化高的腺癌患者易發(fā)生E21突變。腺癌患者中的EGFR及VEGFR-2基因表達(dá)水平更高,VEGFR-2基因表達(dá)水平與腫瘤分化程度正相關(guān)。EGFR基因與VEGFR-2基因呈現(xiàn)共表達(dá)。
[Abstract]:Objective to investigate the mRNA expression level and EGFR mutation of VEGFR-2 gene in patients with non-small cell lung cancer (NSCLC). To summarize the relationship between EGFR and the clinicopathological features of non-small cell lung cancer, and analyze the correlation between gene expression level, and explore the mechanism of EGFR signaling pathway and VEGF/VEGFR signal pathway. To provide a theoretical basis for the rational use of antiepidermal growth factor receptor and antiangiogenic targeted drugs in patients with NSCLC. A total of 128 patients with non-small cell lung cancer (NSCLC) were diagnosed from 2014 to 2015 in thoracic surgery department of PLA General Hospital. To record the age, sex, smoking history, pathological type, degree of differentiation and TNM staging, and other relevant clinical information. The mutation of EGFR E18-21 gene and the mRNA expression of EGFR and VEGFR-2 genes in tumor cells were quantitatively detected by liquid phase microarray technique. Results the mutation rate of EGFR gene was 47.7% in this group. The mutation rate of E19 gene was 21.1and the mutation rate of E21 gene was 26.6%. No E18 or E20 gene mutation. EGFR E19 gene mutation was significantly correlated with smoking history (0.238, p 0.01). The mutation of EGFR E21 gene was associated with the pathological type of the tumor, r-0.213p0.05) and the degree of differentiation of the tumor, r-0.190. The expression of EGFR gene was correlated with the pathological type of tumor. The gene expression of p0.01n.VEGFR-2 and the pathological type of tumor were 0.271p0.01) and the degree of differentiation was 0.237 (P < 0.05). There was a significant correlation between the gene expression of VEGFR-2 and the gene expression of VEGFR-2. Conclusion the mutation of EGFR is more likely to occur in exon 1921. Among them, E19 mutation was easy to occur in patients without smoking history, and E21 mutation was easy to occur in well-differentiated adenocarcinoma patients. The EGFR and VEGFR-2 gene expression levels in adenocarcinoma patients were higher than those in non-smoking patients. The expression level of VEGFR-2 gene was positively correlated with the degree of tumor differentiation. EGFR gene and VEGFR-2 gene co-expressed.
【學(xué)位授予單位】：中國(guó)人民解放軍醫(yī)學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類(lèi)號(hào)】：R734.2
，

本文編號(hào)：1447589